Eli Lilly & Biolojic: Innovative treatments by Artificial intelligence for diabetes!

Eli Lilly & Biolojic: Innovative treatments by Artificial intelligence for diabetes!  Multispecific antibodies treat diabetes! Eli Lilly and Biolojic have reached a cooperation: using artificial intelligence to develop innovative treatments for diabetes!

Novartis recently announced that the Phase 3 CANOPY-2 study (NCT03626545) evaluating the IL-1β inhibitor canakinumab (canakinumab, ACZ885) combined with the chemotherapy drug docetaxel in the treatment of non-small cell lung cancer (NSCLC) has not reached the total The primary end point of survival (OS).

The study was carried out in 237 adult patients with locally advanced or metastatic NSCLC whose disease progressed during or after previous platinum-based chemotherapy and PD-(L)1 inhibitor treatment.

Researchers from Novartis and CANOPY-2 will analyze the data and announce the results at an upcoming medical conference. John Tsai, MD, Head of Global Drug Development and Chief Medical Officer of Novartis, said: “Although the results of the CANOPY-2 study are not what we hoped for, these data provide us with valuable insights into IL-1β inhibition. Ongoing The phase III study of non-small cell lung cancer continues to evaluate canakinumab in an early treatment setting.

We sincerely thank the patients and clinical researchers who participated in the CANOPY-2 study for their cooperation. “

Canakinumab is the active pharmaceutical ingredient of Novartis’ anti-inflammatory drug Ilaris (common name: canakimumab). Ilaris has been approved for multiple indications, including systemic juvenile idiopathic arthritis (sJIA), adult Still’s disease (AOSD), refractory acute idiopathic arthritis, many rare and unique types of periodic Fever syndrome (PFS). The approved indications for Ilaris vary in different countries.

Canakinumab (canakinumab) is a human monoclonal antibody that has high affinity and selective binding to human interleukin-1β (IL-1β), and neutralizes by blocking its interaction with the receptor Activity of IL-1β.

By neutralizing IL-1β, preliminary evidence shows that canakinumab can inhibit pro-tumor inflammation (PTI):

(1) Enhance the anti-tumor immune response;

(2) Reduce tumor cell proliferation, survival and invasiveness;

(3) Weaken tumor angiogenesis. PTI promotes tumor development by driving the carcinogenic process and suppressing the anti-tumor immune response.

Canakinumab is the first IL-1β inhibitor of its kind in non-small cell lung cancer (NSCLC) PTI. The CANOPY clinical trial project aims to help answer the key question of the role of IL-1β in PTI in lung cancer. The project has a number of clinical trials, using a unique combination of treatments to evaluate canakinumab for different disease stages.

Currently, two phase 3 CANOPY studies are continuing to evaluate the application of canakinumab in first-line and adjuvant therapy.

• CANOPY-1 (NCT03631199) study is evaluating canakinumab combined with anti-PD-1 therapy Keytruda (corrida, pembrolizumab) and platinum-containing dual-effect chemotherapy for the first-line treatment of locally advanced or metastatic NSCLC adult patients. The final results will be announced before the end of the year.

• The CANOPY-A (NCT03447769) study is evaluating the use of canakinumab for adjuvant treatment after surgical resection and cisplatin chemotherapy. The purpose is to determine whether adjuvant canakinumab treatment can prevent cancer recurrence. The study has enrolled more than 950 patients so far It is expected that a total of 1,500 patients will be enrolled.

(source:internet, reference only)

Disclaimer of medicaltrend.org